BMS-488043 is primarily investigated for its potential in antiviral therapies, particularly in the treatment of HIV infections. It functions as an entry inhibitor, targeting the gp120 protein on the surface of the HIV virus. By binding to gp120, it prevents the virus from attaching to and entering human CD4+ T cells, a critical step in the viral lifecycle. This mechanism makes it a promising candidate for combination antiretroviral therapy, especially for patients with drug-resistant strains of HIV. Research is ongoing to evaluate its efficacy, safety, and potential use in reducing viral load and improving immune function in HIV-positive individuals.